Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine vs Pramipexole vs Quetiapine Augmentation in Treatment-Resistant Depression
NCT04936126Phase 4Unknown
- Sponsor
- AIIMS New Delhi
- Start
- Aug 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of amantadine and pramipexole in treatment-resistant depression (TRD) (3 arms), sponsored by AIIMS New Delhi. Primary endpoint: Hamilton Depression Scale at 8 weeks. Status: unknown.
02
Drugs
amantadinepramipexole
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT04936126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04936126.